Paclitaxel

Name: Paclitaxel
Brand: MedChemExpress
SKU: HY-B0015
Rating: 5.0 (266 reviews)

Cat. No.: HY-B0015 Purity: 99.97%: Data Sheet
SDS

COA
Handling Instructions
FAQs
Technical Support

Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.

For research use only. We do not sell to patients.

CAS No. : 33069-62-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 266 publication(s) in Google Scholar

Other Forms of Paclitaxel:

254 Publications Citing Use of MCE Paclitaxel

Proliferation Assay

Cell Viability Assay

RT-PCR

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]; The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel (50 nM) plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin] for 48h.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]; Paclitaxel （10 μM；3-5 天）可降低肺癌类器官-3（LCO-3）的活性，对LCO-1和LCO-2的活性影响不显著。

: Paclitaxel purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Jun 18;18(24):15864-15877. [Abstract]; Paclitaxel (PTX, 0.1–1 μM, 24 h) increases COX-2 mRNA expression in 4T1 cells in a dose-dependent manner and induces elevated PGE2 release in the culture medium.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Apr 23, 21(5), 259.; Paclitaxel (PTX; 3.125, 6.25, 12.5, 25, 50, 100 nM; 48 h) reduces the viability of Hela, SiHa, and C33A cells in a dose-dependent manner.(3.125 nM for Hela cells, 100 nM for SiHa and C33A cells)

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Apr 23, 21(5), 259.; Paclitaxel (PTX; 50 nM; 48 h) increases the expression of Cleaved-caspase-9 and Cleaved-caspase-3 in Hela cells.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 May 20.; Paclitaxel (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2023 Feb 15.; Paclitaxel (PTX; 0‑100 nM; 72 h) inhibits the viability of MDA‑MB‑231cells.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Arch Cancer Res. 2023 Jan 30.; Paclitaxel (CPT; 10^-6 -12^-10 M; 72 h) demonstrates a strong antitumor activity and an inhibitory of proliferation (IC₅₀ = 6.28 nM) in U937 cells.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]; Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).

: Paclitaxel purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2019 Feb 13;67(6):1656-1665. [Abstract]; Western blot image and statistical analysis of phosphorylated γH2AX levels in HT-29 cells with different treatments after 48 h. Myricetin and PTX used are 32 μM and 100 nM, respectively.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2018 May;1862(5):1134-1147. [Abstract]; The effects of CS1 on polymerized microtubules are also investigated using a cellular tubulin polymer assay. Nocodazole (1 μM) and Paclitaxel (1.5 μM) are used as depolymerization and polymerization controls, respectively.

: Paclitaxel purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Abstract]; Synergistic inhibition of colony formation of ATC cells by E7080 and Paclitaxel. Representative images of colony formation in C643 cells treated with vehicle control (DMSO) or E7080 and Paclitaxel at the indicated concentrations, individually or in combination, are shown in left panel. Quantitative analysis of colony numbers is shown in right panel.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Traditional Cytotoxic Agents

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	5.56 μM Compound: Paclitaxel	Antiproliferative activity against human 143B cells after 48 hrs by MTT assay Antiproliferative activity against human 143B cells after 48 hrs by MTT assay	[PMID: 29223717]
184B5	IC₅₀	2.32 μM Compound: Paclitaxel	Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay	[PMID: 26602827]
1A9	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human 1A9 cells after 3 days by SRB assay Cytotoxicity against human 1A9 cells after 3 days by SRB assay	[PMID: 16038545]
1A9/ptx-10	IC₅₀	157 nM Compound: 1a, PTX	Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay	[PMID: 17263521]
1A9/ptx-22	IC₅₀	160.7 nM Compound: paclitaxel	Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs	[PMID: 19239240]
4T1	IC₅₀	0.001 mM Compound: Taxol	Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by MTT assay	[PMID: 31857837]
769-P	IC₅₀	7.1 μM Compound: Paclitaxel	Cytotoxicity against human 769-P cells by MTT assay Cytotoxicity against human 769-P cells by MTT assay	[PMID: 21875764]
786-0	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
A 172	GI₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human A-172 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A-172 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31945642]
A121	IC₅₀	6.1 nM Compound: Paclitaxel	Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure	[PMID: 9022794]
A2058	IC₅₀	0.0047 μM Compound: Taxol	Cytotoxicity against human A2058 cells after 96 hrs by CellTire-Glo luminescent assay Cytotoxicity against human A2058 cells after 96 hrs by CellTire-Glo luminescent assay	[PMID: 23623678]
A2780	IC₅₀	< 0.001 μM Compound: Paclitaxel	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 23547884]
A2780 ADR	IC₅₀	> 1000 nM Compound: paclitaxel	Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay	[PMID: 23176628]
A2780/Taxol	IC₅₀	> 500 nM Compound: Paclitaxel	Antiproliferative activity against paclitaxel-resistant human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against paclitaxel-resistant human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32339854]
A2780cis	IC₅₀	0.003 μM Compound: Paclitaxel	Growth inhibition of human A2780cis cells after 72 hrs by MTT assay Growth inhibition of human A2780cis cells after 72 hrs by MTT assay	[PMID: 29519737]
A2780S	IC₅₀	12.3 nM Compound: Paclitaxel	Antiproliferative activity against human A2780S cells after 48 hrs by MTT assay Antiproliferative activity against human A2780S cells after 48 hrs by MTT assay	[PMID: 28763646]
A-375	IC₅₀	0.002 μM Compound: PTX	Cytotoxicity against human A375 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 30633861]
A375/TxR	IC₅₀	103.8 nM Compound: Paclitaxel	Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A-431	IC₅₀	0.001 μM Compound: Taxol	Anticancer activity against human A431 cells by MTT assay Anticancer activity against human A431 cells by MTT assay	[PMID: 33316408]
A498	IC₅₀	7.53 μg/mL Compound: Paclitaxel	Anticancer activity against human A498 cells after 24 hrs by MTT assay Anticancer activity against human A498 cells after 24 hrs by MTT assay	[PMID: 25305717]
A549	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
A549/TR	IC₅₀	> 1000 nM Compound: Paclitaxel	Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
ACHN	IC₅₀	0.066 μM Compound: Paclitaxel	Antiproliferative activity against human ACHN cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human ACHN cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
AGS	IC₅₀	< 10 μM Compound: Taxol	Cytotoxicity against human AGS cells after 48 hrs by MTT assay Cytotoxicity against human AGS cells after 48 hrs by MTT assay	[PMID: 22370266]
ARO	IC₅₀	0.0002 μM Compound: taxol	Cytotoxicity against human Aro cells after 72 hrs by MTT assay Cytotoxicity against human Aro cells after 72 hrs by MTT assay	[PMID: 17915851]
ASPC1	IC₅₀	20 nM Compound: 2	Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay	[PMID: 18081257]
B16	IC₅₀	0.04 μM Compound: taxol	Cytotoxicity against mouse B16 after 48 hrs by SRB assay Cytotoxicity against mouse B16 after 48 hrs by SRB assay	[PMID: 21044847]
B16-F0	IC₅₀	0.021 μM Compound: PTX	Antiproliferative activity against mouse B16-F0 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against mouse B16-F0 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 32650183]
B16-F1	GI₅₀	0.02 μM Compound: Taxol	Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay	[PMID: 32199690]
B16-F10	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
BC1 cell line	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human BC1 cells after 72 hrs by SRB assay Cytotoxicity against human BC1 cells after 72 hrs by SRB assay	[PMID: 12088425]
BEAS-2B	IC₅₀	< 0.1 μM Compound: Paclitaxel	Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
Bel-7402	IC₅₀	< 0.1 μM Compound: Taxol	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27887843]
Bel7402/5-FU	IC₅₀	10.54 μM Compound: TAX	Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay	[PMID: 30677614]
BEL-7404 tumor cell line	IC₅₀	0.82 μM Compound: Taxol	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 22153338]
BeWo	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27010926]
BGC-823	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
BNL	IC₅₀	0.2 μM Compound: Taxol	Cytotoxicity against mouse BNL cells by MTT assay Cytotoxicity against mouse BNL cells by MTT assay	[PMID: 16539377]
Breast carcinoma cell	IC₅₀	7.8 μM Compound: Taxol	Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay	[PMID: 30831408]
BT-474	IC₅₀	8.36 nM Compound: Paclitaxel	Cytotoxicity against human BT474 cells after 4 days by MTS/cell proliferation assay Cytotoxicity against human BT474 cells after 4 days by MTS/cell proliferation assay	[PMID: 25098528]
BT-549	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
BXPC-3	IC₅₀	0.09 μM Compound: Paclitaxel	Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
C6	IC₅₀	3.1 nM Compound: paclitaxel	Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test	[PMID: 18465846]
Caco-2	IC₅₀	0.007 μg/mL Compound: taxol	Cytotoxicity against human Caco-2 cell line by MTT assay Cytotoxicity against human Caco-2 cell line by MTT assay	[PMID: 16297622]
CAKI-1	GI₅₀	158 nM Compound: Paclitaxel	Cytotoxicity against human CAKI-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human CAKI-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
CAPAN-1	IC₅₀	3.3 nM Compound: Taxol	Cytotoxicity against human Capan1 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human Capan1 cells after 48 hrs by sulforhodamine B assay	[PMID: 30528697]
Capan-2	IC₅₀	1.7 x 10^-2 μM Compound: Paclitaxel	Cytotoxicity against human Capan2 cells by MTT assay Cytotoxicity against human Capan2 cells by MTT assay	[PMID: 27441892]
Ca-Ski	IC₅₀	2.9 μM Compound: Paclitaxel	Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay	[PMID: 29407986]
CCRF-CEM	IC₅₀	0.0012 μM Compound: Taxol	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22507893]
CEM-VLB	IC₅₀	3340 nM Compound: Pac	Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay	[PMID: 21920638]
CFPAC-1	IC₅₀	0.047 μM Compound: Paclitaxel	Cytotoxicity against human CFPAC-1 cells after 72 hrs by SRB assay Cytotoxicity against human CFPAC-1 cells after 72 hrs by SRB assay	[PMID: 20800500]
CHO	IC₅₀	170 nM Compound: Pac	Antiproliferative activity against human CHO after 48 hrs by SRB assay Antiproliferative activity against human CHO after 48 hrs by SRB assay	[PMID: 21920638]
CHO-K1	IC₅₀	15.99 μM Compound: paclitaxel	Cytotoxicity against CHOK1 cells after 72 hrs by MTT assay Cytotoxicity against CHOK1 cells after 72 hrs by MTT assay	[PMID: 19053781]
CHO-TAX 5-6	IC₅₀	520 nM Compound: Pac	Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay	[PMID: 21920638]
CHO-VV 3-2	IC₅₀	140 nM Compound: Pac	Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay	[PMID: 21920638]
CNE-2	IC₅₀	0.003 μM Compound: TAX, Taxol	Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method	[PMID: 25061803]
Col2	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human Col2 cells after 72 hrs by SRB assay Cytotoxicity against human Col2 cells after 72 hrs by SRB assay	[PMID: 12088425]
COLO 205	IC₅₀	0.003 μM Compound: Taxol	Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay	[PMID: 25091926]
COLO 320DM	IC₅₀	0.0045 μg/mL Compound: taxol	Cytotoxicity against human COLO320DM cell line by MTT assay Cytotoxicity against human COLO320DM cell line by MTT assay	[PMID: 16297622]
CT26	IC₅₀	> 10 μM Compound: Taxol	Cytotoxicity against mouse CT26 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
CWR22R	IC₅₀	0.08 μM Compound: Paclitaxel	Cytotoxicity against human 22Rv1 cells by MTT assay Cytotoxicity against human 22Rv1 cells by MTT assay	[PMID: 21875764]
Daoy	IC₅₀	0.002 μM Compound: Paclitaxel	Cytotoxicity against human DaOY cells after 96 hrs by MTT assay Cytotoxicity against human DaOY cells after 96 hrs by MTT assay	[PMID: 29279273]
DG-75	IC₅₀	10 nM Compound: Taxol	Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay	[PMID: 21227702]
DLD-1	IC₅₀	0.05 μM Compound: paclitaxel	Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay	[PMID: 21563750]
DU-145	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
ECa-109 cell line	IC₅₀	0.14 μM Compound: paclitaxel	Cytotoxicity against human EC109 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human EC109 cells assessed as reduction in cell viability by MTS assay	[PMID: 25760674]
EKVX	IC₅₀	150 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human EKVX cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human EKVX cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
EL4	IC₅₀	0.0001 μM Compound: Taxol	Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 27010926]
Fibroblast	IC₅₀	< 0.001 μM Compound: Taxol	Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
GES1	IC₅₀	106.2 μM Compound: Taxol	Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 21664827]
H22	IC₅₀	0.084 μM Compound: Taxol	Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32339853]
H69AR	IC₅₀	2.5 nM Compound: paclitaxel	Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay	[PMID: 17286393]
HaCaT	IC₅₀	0.002 μM Compound: Taxol	Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HCC 2998	GI₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human HCC2998 cells by sulforhodamine B assay Cytotoxicity against human HCC2998 cells by sulforhodamine B assay	[PMID: 21839640]
HCC1806	IC₅₀	0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HCC1806 cells after 24 hrs by CCK8 assay Antiproliferative activity against human HCC1806 cells after 24 hrs by CCK8 assay	[PMID: 30392953]
HCC1937	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay	[PMID: 25872984]
HCT-116	IC₅₀	< 0.0008 μM Compound: Taxol	Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis	[PMID: 19665384]
HCT-116/VM46	IC₅₀	> 200 nM Compound: Taxol	Growth inhibition of human HCT116/VM46 cells over-expressing P-gp after 72 hrs by phosphatase assay Growth inhibition of human HCT116/VM46 cells over-expressing P-gp after 72 hrs by phosphatase assay	[PMID: 29439899]
HCT-15	IC₅₀	0.12 μM Compound: Taxol	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 23425970]
HCT-8	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human HCT8 cells after 3 days by SRB assay Cytotoxicity against human HCT8 cells after 3 days by SRB assay	[PMID: 16038545]
HEK293	IC₅₀	0.0039 μM Compound: Paclitaxel	Cytotoxicity against HEK cells after 72 hrs by alamar blue assay Cytotoxicity against HEK cells after 72 hrs by alamar blue assay	[PMID: 20732809]
HEK-293T	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 33310292]
HeLa	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31390200]
HeLa S3	IC₅₀	0.013 μM Compound: Paclitaxel	Antiproliferative activity against human HeLaS3 cells after 72 hrs by MTT assay Antiproliferative activity against human HeLaS3 cells after 72 hrs by MTT assay	[PMID: 29803003]
Hep 3B2	IC₅₀	0.02 μM Compound: Paclitaxel	Cytotoxicity activity against human Hep3B cells assessed as growth inhibition measured after 48 hrs by MTT assay Cytotoxicity activity against human Hep3B cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 27627130]
HEp-2	IC₅₀	0.11 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
HepG2	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HEY	IC₅₀	104.1 nM Compound: Paclitaxel	Cytotoxicity against human HEY cells after 48 hrs by MTT assay Cytotoxicity against human HEY cells after 48 hrs by MTT assay	[PMID: 28719204]
HFF-1	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human HFF1 after 24 hrs by MTT assay Cytotoxicity against human HFF1 after 24 hrs by MTT assay	[PMID: 30387611]
HGC-27	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
HL-60	IC₅₀	< 0.008 μM Compound: Taxol	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
HL-60(TB)	GI₅₀	4 nM Compound: Paclitaxel	Cytotoxicity against human HL-60(TB) cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HL-60(TB) cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HOP-62	GI₅₀	19 nM Compound: Paclitaxel	Cytotoxicity against human HOP-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HOP-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
HOP-92	GI₅₀	25 nM Compound: Paclitaxel	Cytotoxicity against human HOP-92 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human HOP-92 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
Hs-578T	GI₅₀	0.003 μM Compound: Paclitaxel	Cytotoxicity against human Hs578T cells by sulforhodamine B assay Cytotoxicity against human Hs578T cells by sulforhodamine B assay	[PMID: 21839640]
HSC-T6	IC₅₀	0.75 μg/mL Compound: paclitaxel	Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay	[PMID: 19928884]
HT-1080	IC₅₀	0.15 nM Compound: Pac	Antiproliferative activity against human HT1080 after 48 hrs by SRB assay Antiproliferative activity against human HT1080 after 48 hrs by SRB assay	[PMID: 21920638]
HT-29	IC₅₀	< 10 μM Compound: Taxol	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 22370266]
Huh-7	IC₅₀	0.005 μM Compound: Paclitaxel	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32633512]
HUVEC	IC₅₀	< 0.05 μM Compound: Paclitaxel	Antiproliferative activity against human HUVEC cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human HUVEC cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
IGROV-1	IC₅₀	0.06 μM Compound: 3	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis	[PMID: 19833515]
IMR-32	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
J774	ED₅₀	0.09 μM Compound: Taxol	Concentration that inhibits the cell division by 50% after 72 h Concentration that inhibits the cell division by 50% after 72 h	[PMID: 7910216]
J774.2	ED₅₀	0.09 μM Compound: taxol	Concentration that inhibits cell division by 50% after 72 hr for J774.2 cells was determined Concentration that inhibits cell division by 50% after 72 hr for J774.2 cells was determined	[PMID: 1672157]
Jurkat	IC₅₀	< 0.01 μM Compound: Taxol	Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
K562	IC₅₀	> 100 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay	10.1007/s00044-012-0436-9
Kasumi 1	IC₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34704758]
KB	IC₅₀	< 0.1 μg/mL Compound: paclitaxel	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 11473432]
KB 3-1	IC₅₀	0.0005 μM Compound: Paclitaxel	Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
KB-V1	IC₅₀	> 2.3 μM Compound: 1	Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay	[PMID: 12088425]
KETR3	IC₅₀	0.05 μM Compound: Taxol	Anticancer activity against human KETR3 cells by MTT assay Anticancer activity against human KETR3 cells by MTT assay	[PMID: 33316408]
KM12	GI₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human KM12 cells by sulforhodamine B assay Cytotoxicity against human KM12 cells by sulforhodamine B assay	[PMID: 21839640]
KU812 cell line	IC₅₀	5.3 nM Compound: Taxol	Cytotoxicity against human KU812 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human KU812 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
L02	IC₅₀	< 0.1 μM Compound: Paclitaxel	Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay	[PMID: 34303874]
L1210	IC₅₀	> 5 μM Compound: Paclitaxel	Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay	[PMID: 21705223]
L929	IC₅₀	32.95 μg/mL Compound: Paclitaxel	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 48 hrs Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 48 hrs	[PMID: 31607609]
LC-2-ad	IC₅₀	2.5 nM Compound: 28	Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay	[PMID: 25625617]
Lewis lung carcinoma cell line	IC₅₀	0.189 μM Compound: Paclitaxel	Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
LNCaP	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 12088425]
LOX IMVI	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human LOX IMVI cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human LOX IMVI cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
LS174T	IC₅₀	9.5 nM Compound: Taxol	Antiproliferative activity against human LS174T cells after 72 hrs by phosphatase assay Antiproliferative activity against human LS174T cells after 72 hrs by phosphatase assay	[PMID: 28857558]
LS180	IC₅₀	2.8 nM Compound: Paclitaxel	Cytotoxicity against human LS180 cells after 48 hrs by MTT assay Cytotoxicity against human LS180 cells after 48 hrs by MTT assay	[PMID: 29373791]
LT12 tumor cell line	IC₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay	[PMID: 21705223]
Lu1	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 12088425]
LU-99A	IC₅₀	5.2 nM Compound: 28	Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay	[PMID: 25625617]
M14	IC₅₀	0.007 μM Compound: Paclitaxel	Antiproliferative activity against human M14 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human M14 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
M21	GI₅₀	0.037 μM Compound: Pac	Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method	[PMID: 18617414]
Malme-3M	GI₅₀	50 nM Compound: Paclitaxel	Cytotoxicity against human Malme-3M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human Malme-3M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
MCF-10A	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
MCF7	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
MCF7/PTX	IC₅₀	54.8 μM Compound: PTX	Cytotoxicity against human MCF7/PTX cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7/PTX cells incubated for 48 hrs by MTT assay	[PMID: 30913525]
MCF7-DOX	IC₅₀	585 nM Compound: 1	Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test	[PMID: 16183281]
MCF7R	IC₅₀	0.19 μM Compound: Paclitaxel	Antiproliferative activity against paclitaxel-resistant human MCF7R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against paclitaxel-resistant human MCF7R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
MCF7S	IC₅₀	0.002 μM Compound: Paclitaxel	In vitro cytotoxic activity against growth of human breast carcinoma cell line (MCF-7-S) after 72 hr In vitro cytotoxic activity against growth of human breast carcinoma cell line (MCF-7-S) after 72 hr	[PMID: 15177459]
MCF7-VP	IC₅₀	0.0028 μM Compound: paclitaxel, Taxol	Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay	[PMID: 21680190]
MDA-MB-231	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
MDA-MB-435	IC₅₀	0.0002 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay	[PMID: 32096998]
MDA-MB-435S	IC₅₀	0.009 μM Compound: Taxol	Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 25091926]
MDA-MB-436	IC₅₀	8 nM Compound: PTX	Cytotoxicity against human MDA-MB-436 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-436 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26132075]
MDA-MB-453	IC₅₀	0.7 nM Compound: Paclitaxel	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MDA-MB-468	IC₅₀	0.0061 μM Compound: Paclitaxel	Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 28926237]
MDR	IC₅₀	0.4 μM Compound: paclitaxel	Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs	[PMID: 17181164]
MES-SA	IC₅₀	< 0.001 μM Compound: paclitaxel	Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 19743863]
MES-SA/Dx5	IC₅₀	> 1000 nM Compound: paclitaxel	Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay	[PMID: 17286393]
MGC-803	IC₅₀	0.83 μM Compound: PTX	Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay	[PMID: 27491707]
MIA PaCa-2	IC₅₀	0.1 μM Compound: Paclitaxel	Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
MKN-45	IC₅₀	4 nM Compound: 28	Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MM96L	IC₅₀	> 10 μM Compound: Paclitaxel	Cytotoxicity against human MM96L after 24 hrs by MTT assay Cytotoxicity against human MM96L after 24 hrs by MTT assay	[PMID: 30387611]
MOLM-13	IC₅₀	3.45 nM Compound: PTX	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
MOLT-4	IC₅₀	1.8 nM Compound: Taxol	Cytotoxicity against human MOLT4 cells by MTT assay Cytotoxicity against human MOLT4 cells by MTT assay	[PMID: 23806112]
MRC5	IC₅₀	> 200 μM Compound: Paclitaxel	Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 30798081]
MV4-11	IC₅₀	0.017 μM Compound: Taxol	Antiproliferative activity against human MV411 cells after 72 hrs by MTT assay Antiproliferative activity against human MV411 cells after 72 hrs by MTT assay	[PMID: 30212198]
MX1	IC₅₀	0.035 μM Compound: Taxol	Cytotoxicity against human MX1 cells after 72 hrs by SRB assay Cytotoxicity against human MX1 cells after 72 hrs by SRB assay	[PMID: 21144756]
NALM-6	IC₅₀	0.0041 μM Compound: Paclitaxel	Antiproliferative activity against human NALM6 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay Antiproliferative activity against human NALM6 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay	[PMID: 24852281]
NB-4	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human NB4 cells after 48 hrs by MTT assay Cytotoxicity against human NB4 cells after 48 hrs by MTT assay	[PMID: 24063582]
NCI/ADR-RES	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay	[PMID: 28335606]
NCI-H1299	IC₅₀	0.005 μM Compound: Taxol	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
NCI-H1437	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-H1437 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1437 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
NCI-H1650	IC₅₀	> 1 μM Compound: Taxol	Growth inhibition of human NCI-H1650 cells after 96 hrs by MTT assay Growth inhibition of human NCI-H1650 cells after 96 hrs by MTT assay	[PMID: 28737396]
NCI-H1975	IC₅₀	2.5 nM Compound: PTX	Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay	[PMID: 26132075]
NCI-H1993	GI₅₀	0.004 μM Compound: Paclitaxel	Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay	[PMID: 27218860]
NCI-H2126	IC₅₀	2.5 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H2126 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H2126 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 22871217]
NCI-H226	GI₅₀	3.9 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H23	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H292	IC₅₀	0.006 μM Compound: Taxol	Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 26712098]
NCI-H295R	IC₅₀	0.08 μM Compound: Taxol	Cytotoxicity against human H295R cells by MTT assay Cytotoxicity against human H295R cells by MTT assay	[PMID: 16539377]
NCI-H322M	GI₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay	[PMID: 21839640]
NCI-H358	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human NCI-H358 cells by MTT assay Cytotoxicity against human NCI-H358 cells by MTT assay	[PMID: 23425970]
NCI-H441	IC₅₀	0.15 μM Compound: Taxol	Anticancer activity against human NCI-H441 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human NCI-H441 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
NCI-H460	IC₅₀	< 0.001 μM Compound: Paclitaxel	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
NCI-H520	IC₅₀	8.2 nM Compound: Taxol	Antiproliferative activity against human NCI-H520 cells after 72 hrs by phosphatase assay Antiproliferative activity against human NCI-H520 cells after 72 hrs by phosphatase assay	[PMID: 28857558]
NCI-H522	GI₅₀	15.8 nM Compound: Paclitaxel	Cytotoxicity against human NCI-H522 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H522 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
NCI-H596	IC₅₀	0.035 μM Compound: Taxol	Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay	[PMID: 28395199]
NCI-H69	IC₅₀	1.9 nM Compound: paclitaxel	Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay	[PMID: 17286393]
NCI-H727	IC₅₀	0.01 μM Compound: Taxol	Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
NCI-H838	IC₅₀	0.026 μM Compound: paclitaxel	Cytotoxicity against human NCI-H838 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H838 cells after 72 hrs by MTT assay	[PMID: 19053781]
NCI-N87	IC₅₀	5.9 nM Compound: Taxol	Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay	[PMID: 21296467]
NCM460	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
NFF	IC₅₀	0.0047 μM Compound: Paclitaxel	Cytotoxicity against human NFF after 72 hrs by alamar blue assay Cytotoxicity against human NFF after 72 hrs by alamar blue assay	[PMID: 20732809]
NIH3T3	IC₅₀	0.58 μM Compound: 6	Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25682561]
OCI-Ly1	IC₅₀	0.18 μM Compound: Paclitaxel	Cytotoxicity against human OCI-LY1 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay Cytotoxicity against human OCI-LY1 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay	10.1039/C4MD00573B
OE19	IC₅₀	0.4 μM Compound: taxol	Cytotoxicity against human OE19 cells after 72 hrs by MTT assay Cytotoxicity against human OE19 cells after 72 hrs by MTT assay	[PMID: 17915851]
OE33	IC₅₀	0.2 μM Compound: taxol	Cytotoxicity against human OE33 cells after 72 hrs by MTT assay Cytotoxicity against human OE33 cells after 72 hrs by MTT assay	[PMID: 17915851]
OS-RC-2	IC₅₀	< 0.08 μM Compound: Paclitaxel	Cytotoxicity against human OS-RC2 cells by MTT assay Cytotoxicity against human OS-RC2 cells by MTT assay	[PMID: 21875764]
OV-90	IC₅₀	5.19 μM Compound: Taxol	Anticancer activity against human OV-90 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human OV-90 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
OVCAR	IC₅₀	0.06 μM Compound: Paclitaxel	Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay	10.1007/s00044-011-9824-9
OVCAR-3	IC₅₀	0.0015 μM Compound: Paclitaxel	Cytotoxicity against human OVCAR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human OVCAR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 31953129]
OVCAR-4	IC₅₀	> 600 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
OVCAR-5	GI₅₀	7.9 nM Compound: Paclitaxel	Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
OVCAR-8	IC₅₀	0.01 μM Compound: Paclitaxel	Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay	[PMID: 29519737]
P388	IC₅₀	> 5 μM Compound: Paclitaxel	Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay	[PMID: 21705223]
P388/ADR	IC₅₀	1636 nM Compound: paclitaxel	Antiproliferative activity against adriamycin resistant P388 cells by ELISA Antiproliferative activity against adriamycin resistant P388 cells by ELISA	[PMID: 17154505]
P388D1	IC₅₀	35 nM Compound: Pac	Antiproliferative activity against human P388D1 after 48 hrs by SRB assay Antiproliferative activity against human P388D1 after 48 hrs by SRB assay	[PMID: 21920638]
PA-1	IC₅₀	0.006 μg/mL Compound: taxol	Cytotoxicity against human PA1 cell line by MTT assay Cytotoxicity against human PA1 cell line by MTT assay	[PMID: 16297622]
PANC-1	IC₅₀	< 0.008 μM Compound: Paclitaxel	Growth inhibition of human PANC1 cells after 48 hrs by SRB assay Growth inhibition of human PANC1 cells after 48 hrs by SRB assay	[PMID: 20521771]
PC-14	IC₅₀	4.4 nM Compound: 28	Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay	[PMID: 25625617]
PC-3	IC₅₀	< 0.0008 μM Compound: Taxol	Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis	[PMID: 19665384]
PC-3M	IC₅₀	0.027 μM Compound: paclitaxel	Cytotoxicity against human PC3M cells after 24 hrs by MTT assay Cytotoxicity against human PC3M cells after 24 hrs by MTT assay	[PMID: 19245261]
PC-9	IC₅₀	0.000056 μM Compound: Taxol	Antiproliferation activity against human PC9 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human PC9 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
PG-49 cell line	IC₅₀	0.31 nM Compound: Paclitaxel	Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in PG-49 cell line by MTT assay. Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in PG-49 cell line by MTT assay.	[PMID: 12392737]
PPC-1	IC₅₀	3.4 nM Compound: Paclitaxel	Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay	[PMID: 15801848]
PT-45	IC₅₀	0.005 μM Compound: taxol	Cytotoxicity against human PT45 cells after 72 hrs by MTT assay Cytotoxicity against human PT45 cells after 72 hrs by MTT assay	[PMID: 17915851]
Ramos	IC₅₀	3.35 nM Compound: PTX	Antiproliferative activity against human Ramos cells incubated for 72 hrs by MTT assay Antiproliferative activity against human Ramos cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
RAW264.7	IC₅₀	> 5 μM Compound: Paclitaxel	Antiproliferative activity against mouse RAW264.7 cells after 18 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against mouse RAW264.7 cells after 18 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
RCC4	IC₅₀	0.1 μM Compound: Taxol	Anticancer activity against human RCC4 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human RCC4 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
RCC4/VHL	IC₅₀	0.06 μM Compound: Taxol	Anticancer activity against human RCC4/VHL cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human RCC4/VHL cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
RD	IC₅₀	> 10000 nM Compound: PTX	Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26132075]
Rhabdomyosarcoma cell	IC₅₀	8.4 nM Compound: Paclitaxel	Antiproliferative activity against human Rhabdomyosarcoma cells after 96 hrs by MTS assay Antiproliferative activity against human Rhabdomyosarcoma cells after 96 hrs by MTS assay	[PMID: 26386818]
RKO	IC₅₀	> 10 μM Compound: paclitaxel	Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay	[PMID: 19220018]
RL	IC₅₀	0.003 μM Compound: paclitaxel	Antiproliferative activity against human RL cells after 72 hrs by MTT assay Antiproliferative activity against human RL cells after 72 hrs by MTT assay	[PMID: 19743863]
RPMI-7951	IC₅₀	0.013 μM Compound: Paclitaxel	Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
RPMI-8226	IC₅₀	1.53 μM Compound: PTX	Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells	[PMID: 31200238]
RT-112	IC₅₀	0.07 μM Compound: Paclitaxel	Cytotoxicity against human RT-112 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human RT-112 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 33459007]
RWPE-1	IC₅₀	0.7 μg/mL Compound: PTX	Cytotoxicity against human RWPE1 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human RWPE1 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24794748]
RXF 393	GI₅₀	15.8 nM Compound: Paclitaxel	Cytotoxicity against human RXF 393 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human RXF 393 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SAOS-2	IC₅₀	0.35 μM Compound: Paclitaxel	Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
SF-268	IC₅₀	0.01 μM Compound: Paclitaxel	Cytotoxicity against human SF268 cells after 48 hrs by XTT assay Cytotoxicity against human SF268 cells after 48 hrs by XTT assay	[PMID: 21705223]
SF-295	IC₅₀	0.056 μM Compound: Paclitaxel	Antiproliferative activity against human SF295 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human SF295 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
SF-539	GI₅₀	5 nM Compound: Paclitaxel	Cytotoxicity against human SF-539 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SF-539 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SGC-7901	IC₅₀	0.2 μg/mL Compound: Taxol	Cytotoxicity against human SGC7901 cells after 48 hrs by SRB assay Cytotoxicity against human SGC7901 cells after 48 hrs by SRB assay	[PMID: 26351042]
SH-SY5Y	IC₅₀	0.004 μM Compound: Taxol	Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay	[PMID: 22222040]
SiHa	IC₅₀	1.4 μM Compound: Paclitaxel	Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay	[PMID: 30920216]
SJSA-1	IC₅₀	3.2 nM Compound: taxol	Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay	[PMID: 18243696]
SK-BR-3	IC₅₀	> 100 nM Compound: PXL	Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay	[PMID: 25241925]
SK-HEP1	IC₅₀	0.24 μM Compound: Taxol	Cytotoxicity against human SKHEP1 cells by MTT assay Cytotoxicity against human SKHEP1 cells by MTT assay	[PMID: 23425970]
SK-MEL	IC₅₀	4.1 μM Compound: paclitaxel	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay	[PMID: 19879765]
SK-MEL-2	IC₅₀	0.009 μM Compound: Paclitaxel	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
SK-MEL-24	IC₅₀	4.73 μM Compound: Paclitaxel	Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
SK-MEL-28	IC₅₀	1.07 μM Compound: PTX	Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37197457]
SK-MEL3	IC₅₀	4.73 μM Compound: PTX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37197457]
SK-MEL-5	IC₅₀	0.15 μM Compound: paclitaxel	Cytotoxicity against human SK-MEL-5 cells by MTT assay Cytotoxicity against human SK-MEL-5 cells by MTT assay	[PMID: 22691179]
SK-MES-1	IC₅₀	13.5 nM Compound: Paclitaxel	Cytotoxicity against human SKMES1 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human SKMES1 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay	[PMID: 26985296]
SK-N-SH	GI₅₀	2.19 μM Compound: Paclitaxel	Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 3 days by MTT assay Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 3 days by MTT assay	[PMID: 21889341]
SK-OV-3	IC₅₀	< 0.0001 μM Compound: paclitaxel	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 22506620]
SMMC-7721	IC₅₀	< 0.008 μM Compound: Paclitaxel	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32628478]
SN12C	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human SN12C cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SN12C cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SNB-19	GI₅₀	10 nM Compound: Paclitaxel	Cytotoxicity against human SNB-19 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SNB-19 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SNB-75	GI₅₀	0.004 μM Compound: Paclitaxel	Cytotoxicity against human SNB75 cells by sulforhodamine B assay Cytotoxicity against human SNB75 cells by sulforhodamine B assay	[PMID: 21839640]
SNU-387	IC₅₀	0.27 μM Compound: Paclitaxel	Cytotoxicity against human SNU387 cells after 48 hrs by MTT assay Cytotoxicity against human SNU387 cells after 48 hrs by MTT assay	[PMID: 23701597]
SNU-398	IC₅₀	0.6 nM Compound: Taxol	Cytotoxicity against human SNU398 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SNU398 cells after 48 hrs by sulforhodamine B assay	[PMID: 30528697]
SR	GI₅₀	6.3 nM Compound: Paclitaxel	Cytotoxicity against human SR cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human SR cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
SU-DHL-6	GI₅₀	7.9 nM Compound: Paclitaxel	Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay	[PMID: 30878826]
SUP-B15	IC₅₀	8 nM Compound: Taxol	Cytotoxicity against human SUP-B15 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against human SUP-B15 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
SW1573	GI₅₀	1.5 nM Compound: PTX	Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay	[PMID: 31271961]
SW1990	IC₅₀	0.01 μM Compound: Paclitaxel	Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36511661]
SW48	IC₅₀	0.001 μM Compound: paclitaxel	Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay	[PMID: 19743863]
SW480	IC₅₀	< 0.008 μM Compound: Taxol	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36274275]
SW-620	IC₅₀	0.03 μM Compound: Paclitaxel	Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
SW620/AD300	IC₅₀	1.97 μM Compound: Paclitaxel	Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
SW626	IC₅₀	0.00001 μM Compound: 1	Cytotoxicity against human SW626 cells after 72 hrs by SRB assay Cytotoxicity against human SW626 cells after 72 hrs by SRB assay	[PMID: 12088425]
SW780	IC₅₀	1.1 nM Compound: paclitaxel	Cytotoxicity against human SW780 cells after 96 hrs by MTT assay Cytotoxicity against human SW780 cells after 96 hrs by MTT assay	[PMID: 23176628]
T47D	IC₅₀	0.004 μM Compound: paclitaxel	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 19743863]
T98G	IC₅₀	0.012 μM Compound: Taxol	Cytotoxicity against human T98G assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human T98G assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 33310292]
THP-1	IC₅₀	3.01 nM Compound: PTX	Antiproliferative activity against human THP-1 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells incubated for 72 hrs by MTT assay	[PMID: 34648295]
TK-10	GI₅₀	19.9 nM Compound: Paclitaxel	Cytotoxicity against human TK-10 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Cytotoxicity against human TK-10 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 33310545]
U-251	IC₅₀	0.03 μM Compound: taxol	Cytotoxicity against human U251 after 48 hrs by SRB assay Cytotoxicity against human U251 after 48 hrs by SRB assay	[PMID: 21044847]
U2OS	IC₅₀	0.03 μM Compound: Taxol	Anticancer activity against human U2OS cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay Anticancer activity against human U2OS cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay	[PMID: 34399390]
U-87MG ATCC	IC₅₀	0.00038 μM Compound: Taxol	Antiproliferation activity against human U87MG cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferation activity against human U87MG cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 32546298]
U-937	IC₅₀	0.006 μM Compound: PXT	Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
U-937/GTB	IC₅₀	0.0059 μM Compound: Paclitaxel	Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 16562840]
UACC-257	GI₅₀	0.04 μM Compound: Paclitaxel	Cytotoxicity against human UACC257 cells by sulforhodamine B assay Cytotoxicity against human UACC257 cells by sulforhodamine B assay	[PMID: 21839640]
UACC-62	IC₅₀	0.006 μM Compound: Paclitaxel	Antiproliferative activity against human UACC62 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay Antiproliferative activity against human UACC62 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay	[PMID: 28335606]
UACC-812	IC₅₀	0.7 μM Compound: paclitaxel	Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay	[PMID: 19743863]
UO-31	IC₅₀	240 μM Compound: Paclitaxel	Antiproliferative activity against taxane-resistant human UO31 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Antiproliferative activity against taxane-resistant human UO31 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 29995409]
Vero	IC₅₀	> 100 μg/mL Compound: Paclitaxel	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27105027]
WI-38	IC₅₀	> 10 μM Compound: Paclitaxel	Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
WI-38 VA13	IC₅₀	0.0043 μM Compound: Taxol	Growth inhibition of human VA13 cells after 48 hrs by WST8 assay Growth inhibition of human VA13 cells after 48 hrs by WST8 assay	[PMID: 16499322]
WM 266-4	IC₅₀	0.32 nM Compound: Taxol	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]
WRL68	IC₅₀	0.0035 μg/mL Compound: taxol	Cytotoxicity against human WRL68 cell line by MTT assay Cytotoxicity against human WRL68 cell line by MTT assay	[PMID: 16297622]
ZR-75-1	IC₅₀	> 100 nM Compound: PXL	Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay	[PMID: 25241925]

In Vitro

Paclitaxel (20 nM; 48 hours) induces programmed cell death and exists a block at the G2/M phase of the cell cycle^[1].
Paclitaxel (20 nM; 48 hours) induces a consistent increase in the level of p53^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	MCF-7, MDA-MB-231 cells
Concentration:	20 nM
Incubation Time:	48 hours
Result:	Induced programmed cell death.

Cell Cycle Analysis^[1]

Cell Line:	MCF-7, MDA-MB-231 cells
Concentration:	20 nM
Incubation Time:	48 hours
Result:	>60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament.

Western Blot Analysis^[1]

Cell Line:	MCF-7 cells (harboring wild-type p53)
Concentration:	20 nM
Incubation Time:	48 hours
Result:	Induced a consistent increase in the level of p53.

In Vivo

Paclitaxel (1-20 mg/kg; i.p.; 1 time/2 days for five cycles) obviously induces liver metastases at the low-Paclitaxel group with little influence on primary tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-231 xenograft-bearing mice^[3]
Dosage:	1, 20 mg/kg
Administration:	Intraperitoneal injection; five cycles (1 time/2 days)
Result:	Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group.

Clinical Trial

Molecular Weight

853.91

Formula

C₄₇H₅₁NO₁₄

CAS No.

33069-62-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (117.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1711 mL	5.8554 mL	11.7108 mL
5 mM	0.2342 mL	1.1711 mL	2.3422 mL
10 mM	0.1171 mL	0.5855 mL	1.1711 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (2.44 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 10 mg/mL (11.71 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (11.71 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (286 KB) SDS (806 KB)

COA (261 KB) HNMR (306 KB) RP-HPLC (242 KB) LCMS (88 KB) Elemental Analysis Report (117 KB)

Handling Instructions (2659 KB)

References

[1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9. [Content Brief]

[2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36. [Content Brief]

[3]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52. [Content Brief]

[4]. Pan Z, et al. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3. [Content Brief]

[5]. Cadamuro M, et al. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Jun 21. [Content Brief]

[6]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Jun 16. [Content Brief]

[7]. Yilmaz E, et al. Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy. Neuroscience. 2015 Aug 6;300:210-8. [Content Brief]

[8]. Jing C, et al. E7080 enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1711 mL	5.8554 mL	11.7108 mL	29.2771 mL
	5 mM	0.2342 mL	1.1711 mL	2.3422 mL	5.8554 mL
	10 mM	0.1171 mL	0.5855 mL	1.1711 mL	2.9277 mL
	15 mM	0.0781 mL	0.3904 mL	0.7807 mL	1.9518 mL
	20 mM	0.0586 mL	0.2928 mL	0.5855 mL	1.4639 mL
	25 mM	0.0468 mL	0.2342 mL	0.4684 mL	1.1711 mL
	30 mM	0.0390 mL	0.1952 mL	0.3904 mL	0.9759 mL
	40 mM	0.0293 mL	0.1464 mL	0.2928 mL	0.7319 mL
	50 mM	0.0234 mL	0.1171 mL	0.2342 mL	0.5855 mL
	60 mM	0.0195 mL	0.0976 mL	0.1952 mL	0.4880 mL
	80 mM	0.0146 mL	0.0732 mL	0.1464 mL	0.3660 mL
	100 mM	0.0117 mL	0.0586 mL	0.1171 mL	0.2928 mL

Paclitaxel Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Paclitaxel33069-62-4Microtubule/TubulinADC CytotoxinApoptosisAutophagyADC PayloadInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Paclitaxel

Customer Review

Other Forms of Paclitaxel:

Paclitaxel Related Antibodies

254 Publications Citing Use of MCE Paclitaxel

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Paclitaxel Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Paclitaxel Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report